Published in Cancer Res on December 15, 2005
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm (2009) 1.38
Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res (2009) 1.34
Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol (2012) 1.33
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des (2010) 1.23
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
Combinatorial peptide libraries: mining for cell-binding peptides. Chem Rev (2013) 1.07
Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol (2012) 1.05
Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev (2012) 1.05
Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med (2009) 1.04
Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther (2008) 1.04
Challenges in development of targeted liposomal therapeutics. AAPS J (2012) 1.03
Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol Pharm (2012) 1.00
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol (2009) 0.95
Intratumoral drug delivery with nanoparticulate carriers. Pharm Res (2011) 0.95
Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm (2010) 0.95
Diamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression. Adv Mater (2013) 0.94
Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids (2011) 0.93
Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano (2014) 0.92
The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv (2010) 0.91
Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev (2013) 0.90
Engineering polymeric aptamers for selective cytotoxicity. J Am Chem Soc (2011) 0.90
The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro. Ther Deliv (2011) 0.89
Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Devel Ther (2013) 0.88
Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol (2013) 0.88
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomedicine (2014) 0.88
Accelerated killing of cancer cells using a multifunctional single-walled carbon nanotube-based system for targeted drug delivery in combination with photothermal therapy. Int J Nanomedicine (2013) 0.88
Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy. Nanomedicine (2008) 0.87
Effect of peptide-conjugated near-infrared fluorescent quantum dots (NIRF-QDs) on the invasion and metastasis of human tongue squamous cell carcinoma cell line Tca8113 in vitro. Int J Mol Sci (2009) 0.86
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomedicine (2011) 0.86
Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) (2013) 0.86
Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. PLoS One (2012) 0.85
A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. PLoS One (2013) 0.85
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem (2010) 0.83
Ligands located within a cholesterol domain enhance gene delivery to the target tissue. J Control Release (2012) 0.83
Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models. Cancer Sci (2015) 0.82
Imaging, autoradiography, and biodistribution of (188)Re-labeled PEGylated nanoliposome in orthotopic glioma bearing rat model. Cancer Biother Radiopharm (2011) 0.82
Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy. Crit Rev Oncog (2014) 0.81
Lipid-based vectors for siRNA delivery. J Drug Target (2012) 0.81
Development of quinic acid-conjugated nanoparticles as a drug carrier to solid tumors. Biomacromolecules (2013) 0.81
Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy. Int J Nanomedicine (2013) 0.80
The Effect of Molecular Weight, PK, and Valency on Tumor Biodistribution and Efficacy of Antibody-Based Drugs. Transl Oncol (2013) 0.79
Bionanotechnology and the future of glioma. Surg Neurol Int (2015) 0.78
Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. Int J Nanomedicine (2014) 0.78
Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res (2010) 0.78
Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy. Int J Mol Sci (2015) 0.78
Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. J Drug Deliv (2013) 0.76
Radionuclide therapy using (131)I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression. J Cancer Res Clin Oncol (2015) 0.76
Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma. Curr Neuropharmacol (2016) 0.75
Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs (2016) 0.75
Multiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiency. Int J Nanomedicine (2015) 0.75
In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes. Int J Nanomedicine (2017) 0.75
The new era of nanotechnology, an alternative to change cancer treatment. Drug Des Devel Ther (2017) 0.75
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther (2006) 2.10
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci (2008) 1.67
Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol (2004) 1.61
Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci (2002) 1.48
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Characterization of biofilm formation by clinical isolates of Mycobacterium avium. J Med Microbiol (2003) 1.45
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res (2006) 1.43
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett (2008) 1.34
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res (2003) 1.33
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol (2006) 1.29
Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat (2003) 1.27
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol (2006) 1.26
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg (2008) 1.25
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res (2004) 1.25
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22
Real-time imaging and quantification of brain delivery of liposomes. Pharm Res (2006) 1.22
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging (2007) 1.21
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol (2007) 1.21
Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods (2006) 1.17
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer (2012) 1.13
Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res (2012) 1.12
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (2002) 1.08
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog (2005) 1.06
Novel calibration method for flow cytometric fluorescence resonance energy transfer measurements between visible fluorescent proteins. Cytometry A (2005) 1.06
Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther (2008) 1.04
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol (2007) 1.04
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res (2005) 1.03
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging (2005) 1.02
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat (2011) 1.01
Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va. Biochemistry (2002) 1.00